A near normal distribution of IQ in Fragile X Syndrome.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
04 Oct 2024
Historique:
received: 27 04 2023
accepted: 19 09 2024
medline: 5 10 2024
pubmed: 5 10 2024
entrez: 4 10 2024
Statut: epublish

Résumé

Fragile X Syndrome (FXS) is an X-linked disorder leading to the loss of expression of FMR1-protein product, FMRP. The absence or deficiency of FMRP is thought to result in the characteristic FXS phenotypes, including intellectual disability. Identifying the relationship between FMRP levels and IQ may be critical to better understand underlying mechanisms and advance treatment development and planning. A sample of 143 individuals with FXS (69% male), aged 8-50 years, completed IQ testing and blood draw via venipuncture to determine the relationship between Deviation IQ scores and FMRP levels as well as the distribution of Deviation IQ scores. In both males and females with FXS, higher FMRP levels were associated with higher Deviation IQ. However, this relationship was no longer significant when only examining full mutation, fully-methylated males. Yet, both the full and restricted male samples showed a downward shifted but otherwise normal distribution of Deviation IQ scores. Our findings support and extend previous studies establishing molecular markers of disease severity in FXS as well as provide novel evidence of a "FXS IQ standard curve". This latter finding suggests inter-individual variation in Deviation IQ in FXS, especially among males, may be driven by similar factors known to impact cognitive outcomes in typically-developing individuals. Thus, future work aimed at understanding the mechanisms by which FMRP loss leads to intellectual disability should revisit the biological/genetic, socio-environmental, and epigenetic factors contributing to inter-individual variation in IQ in FXS.

Identifiants

pubmed: 39367109
doi: 10.1038/s41598-024-73626-y
pii: 10.1038/s41598-024-73626-y
doi:

Substances chimiques

Fragile X Mental Retardation Protein 139135-51-6
FMR1 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

23058

Subventions

Organisme : National Institute of Child Health and Human Development
ID : K23HD101416
Organisme : National Institute of Child Health and Human Development
ID : U54HD082008

Informations de copyright

© 2024. The Author(s).

Références

Boggs, A. E. et al. Optimization, validation and initial clinical implications of a Luminex-based immunoassay for the quantification of Fragile X protein from dried blood spots. Sci. Rep. Apr. 4 (1), 5617. https://doi.org/10.1038/s41598-022-09633-8 (2022).
doi: 10.1038/s41598-022-09633-8
Straub, D. et al. A sensitive and reproducible qRT-PCR assay detects physiological relevant trace levels of FMR1 mRNA in individuals with Fragile X syndrome. Sci. Rep. Mar.7 (1), 3808. https://doi.org/10.1038/s41598-023-29786-4 (2023).
doi: 10.1038/s41598-023-29786-4
Kirchgessner, C. U., Warren, S. T. & Willard, H. F. X inactivation of the FMR1 fragile X mental retardation gene. J. Med. Genet. Dec.32 (12), 925–929. https://doi.org/10.1136/jmg.32.12.925 (1995).
doi: 10.1136/jmg.32.12.925
Meng, L. et al. The association between mosaicism type and cognitive and behavioral functioning among males with fragile X syndrome. Am J Med Genet A. ;188(3):858–866. doi: https://doi.org/10.1002/ajmg.a.62594 (2022).
Loesch, D. Z. et al. Effect of the deficits of fragile X mental retardation protein on cognitive status of fragile x males and females assessed by robust pedigree analysis. J. Dev. Behav. Pediatr. Dec.23 (6), 416–423 (2002).
doi: 10.1097/00004703-200212000-00004
Loesch, D. Z. et al. Effect of the fragile X status categories and the fragile X mental retardation protein levels on executive functioning in males and females with fragile X. Neuropsychol. Oct.17 (4), 646–657. https://doi.org/10.1037/0894-4105.17.4.646 (2003).
doi: 10.1037/0894-4105.17.4.646
Loesch, D. Z., Huggins, R. M. & Hagerman, R. J. Phenotypic variation and FMRP levels in fragile X. Ment Retard. Dev. Disabil. Res. Rev.10 (1), 31–41. https://doi.org/10.1002/mrdd.20006 (2004).
doi: 10.1002/mrdd.20006 pubmed: 14994286
Roth, M. et al. FMRP levels in human peripheral blood leukocytes correlates with intellectual disability. Diagnostics (Basel) Sep.28 (10). https://doi.org/10.3390/diagnostics11101780 (2021).
Kim, K. et al. Association between IQ and FMR1 protein (FMRP) across the spectrum of CGG repeat expansions. PLoS One. 14 (12), e0226811. https://doi.org/10.1371/journal.pone.0226811 (2019).
doi: 10.1371/journal.pone.0226811 pubmed: 31891607 pmcid: 6938341
Tassone, F. et al. FMRP expression as a potential prognostic indicator in fragile X syndrome. Am. J. Med. Genet. May. 84 (3), 250–261 (1999).
doi: 10.1002/(SICI)1096-8628(19990528)84:3<250::AID-AJMG17>3.0.CO;2-4
Kaufmann, W. E., Abrams, M. T., Chen, W. & Reiss, A. L. Genotype, molecular phenotype, and cognitive phenotype: correlations in fragile X syndrome. Am. J. Med. Genet. Apr. 83 (4), 286–295 (1999).
doi: 10.1002/(SICI)1096-8628(19990402)83:4<286::AID-AJMG10>3.0.CO;2-H
Bailey, D. B., Hatton, D. D., Tassone, F., Skinner, M. & Taylor, A. K. Variability in FMRP and early development in males with fragile X syndrome. Am. J. Ment Retard. Jan. 106 (1), 16–27. https://doi.org/10.1352/0895-8017(2001)1062.0.CO;2 (2001).
doi: 10.1352/0895-8017(2001)1062.0.CO;2
Dyer-Friedman, J. et al. Genetic and environmental influences on the cognitive outcomes of children with fragile X syndrome. J. Am. Acad. Child. Adolesc. Psychiatry Mar.41 (3), 237–244. https://doi.org/10.1097/00004583-200203000-00002 (2002).
doi: 10.1097/00004583-200203000-00002
Rivera, S. M., Menon, V., White, C. D., Glaser, B. & Reiss, A. L. Functional brain activation during arithmetic processing in females with fragile X syndrome is related to FMR1 protein expression. Hum. Brain Mapp. Aug. 16 (4), 206–218. https://doi.org/10.1002/hbm.10048 (2002).
doi: 10.1002/hbm.10048
McDuffie, A. et al. Autism spectrum disorder in children and adolescents with fragile X syndrome: within-syndrome differences and age-related changes. Am. J. Intellect. Dev. Disabil. Jul. 115 (4), 307–326. https://doi.org/10.1352/1944-7558-115.4.307 (2010).
doi: 10.1352/1944-7558-115.4.307
Lessard, M., Chouiali, A., Drouin, R., Sébire, G. & Corbin, F. Quantitative measurement of FMRP in blood platelets as a new screening test for fragile X syndrome. Clin. Genet. Nov. 82 (5), 472–477. https://doi.org/10.1111/j.1399-0004.2011.01798.x (2012).
doi: 10.1111/j.1399-0004.2011.01798.x
Baker, E. K. et al. Tissue mosaicism, <scp > < i > FMR1  expression and intellectual functioning in males with fragile X syndrome</scp >. Am. J. Med. Genet. Part. A. https://doi.org/10.1002/ajmg.a.63027 (2022).
doi: 10.1002/ajmg.a.63027 pubmed: 36493376
Sansone, S. M. et al. Improving IQ measurement in intellectual disabilities using true deviation from population norms. J. Neurodev Disord. 6 (1), 16. https://doi.org/10.1186/1866-1955-6-16 (2014).
doi: 10.1186/1866-1955-6-16 pubmed: 26491488 pmcid: 4613563
Abrams, M. T. et al. Molecular-neurobehavioral associations in females with the fragile X full mutation. Am. J. Med. Genet. Jul. 15 (4), 317–327. https://doi.org/10.1002/ajmg.1320510407 (1994).
doi: 10.1002/ajmg.1320510407
Kover, S. T., Pierpont, E. I., Kim, J. S., Brown, W. T. & Abbeduto, L. A neurodevelopmental perspective on the acquisition of nonverbal cognitive skills in adolescents with fragile X syndrome. Dev. Neuropsychol.38 (7), 445–460. https://doi.org/10.1080/87565641.2013.820305 (2013).
doi: 10.1080/87565641.2013.820305 pubmed: 24138215
Kraan, C. M. et al. DNA methylation at Birth Predicts Intellectual Functioning and Autism Features in children with fragile X syndrome. Int. J. Mol. Sci. Oct.19 (20). https://doi.org/10.3390/ijms21207735 (2020).
Whittington, J., Holland, A. & Webb, T. Relationship between the IQ of people with prader-Willi syndrome and that of their siblings: evidence for imprinted gene effects. J. Intellect. Disabil. Res. May. 53 (5), 411–418. https://doi.org/10.1111/j.1365-2788.2009.01157.x (2009).
doi: 10.1111/j.1365-2788.2009.01157.x
Bellugi, U., Lichtenberger, L., Jones, W., Lai, Z. & St George, M. I. The neurocognitive profile of Williams Syndrome: a complex pattern of strengths and weaknesses. J. Cogn. Neurosci.12 (Suppl 1), 7–29. https://doi.org/10.1162/089892900561959 (2000).
doi: 10.1162/089892900561959 pubmed: 10953231
De Smedt, B. et al. Intellectual abilities in a large sample of children with Velo-Cardio-Facial Syndrome: an update. J. Intellect. Disabil. Res. Sep.51 (Pt 9), 666–670. https://doi.org/10.1111/j.1365-2788.2007.00955.x (2007).
doi: 10.1111/j.1365-2788.2007.00955.x
Raznahan, A. et al. Biological markers of intellectual disability in tuberous sclerosis. Psychol. Med.37 (9), 1293–1304. https://doi.org/10.1017/S0033291707000177 (Sep 2007).
McKinney, W. S., Williford, D. N., Abbeduto, L. & Schmitt, L. M. The impact of social-environmental factors on IQ in syndromic intellectual developmental disabilities. J. Clin. Transl Sci.8 (1), e59. https://doi.org/10.1017/cts.2024.510 (2024).
doi: 10.1017/cts.2024.510 pubmed: 38655457 pmcid: 11036438
King, T. M. & Parisi, M. A. Moving the needle toward equity: what NIH is doing to promote diversity, inclusion, and accessibility in Research on Intellectual and Developmental Disabilities. Am. J. Intellect. Dev. Disabil. Sep.1 (5), 382–385. https://doi.org/10.1352/1944-7558-128.5.382 (2023).
doi: 10.1352/1944-7558-128.5.382
Kover, S. T. & Abbeduto, L. Toward Equity in Research on Intellectual and Developmental Disabilities. Am. J. Intellect. Dev. Disabil. Sep.1 (5), 350–370. https://doi.org/10.1352/1944-7558-128.5.350 (2023).
doi: 10.1352/1944-7558-128.5.350
Hatem, G., Zeidan, J., Goossens, M. & Moreira, C. Normality testing methods and the importance of skewness and kurtosis in statistical analysis. BAU Journal-Science Technol.3 (2), 7 (2022).

Auteurs

Lauren M Schmitt (LM)

Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH, 45229- 3039, USA. lauren.schmitt@cchmc.org.
University of Cincinnati College of Medicine, 3333 Burnet Ave, Cincinnati, OH, 45229-3039, USA. lauren.schmitt@cchmc.org.

Meredith Nelson (M)

University of Cincinnati College of Medicine, 3333 Burnet Ave, Cincinnati, OH, 45229-3039, USA.

Rebecca C Shaffer (RC)

Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH, 45229- 3039, USA.
University of Cincinnati College of Medicine, 3333 Burnet Ave, Cincinnati, OH, 45229-3039, USA.

Craig A Erickson (CA)

Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH, 45229- 3039, USA.
University of Cincinnati College of Medicine, 3333 Burnet Ave, Cincinnati, OH, 45229-3039, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH